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Abstract 
Diamond-Blackfan anemia is a congenital erythroid hypoplasia and is associated with 
physical malformations and predisposition to cancer. Twenty-five percent of patients have 
mutations in gene encoding ribosomal protein S19 (RPS19). Through overexpression of 
ribosomal protein S19 using a lentiviral vector with the spleen focus-forming virus promoter, 
we demonstrated that Diamond-Blackfan anemia phenotype can be successfully treated in 
Rps19 deficient mice. In our present study we assessed efficacy of a clinically relevant 
promoter, the human elongation factor 1α short promoter, with or without Locus control 
region of β-globin gene for treatment of ribosomal protein S19 -deficient Diamond-Blackfan 
anemia. The findings demonstrate, these vectors rescue the proliferation defect and improve 
erythroid development of transduced RPS19 deficient bone marrow cells. Remarkably, bone 
marrow failure and severe anemia in Rps19-deficient mice was cured with enforced 
expression of ribosomal protein S19 driven by elongation factor 1α short promoter. We also 
demonstrate that ribosomal protein S19 -deficient bone marrow cells can be transduced and 
these cells had the capacity to repopulate bone marrow in long-term reconstituted mice. Our 
results collectively demonstrate the feasibility to cure ribosomal protein S19 -deficient 
Diamond-Blackfan anemia using lentiviral vectors with cellular promoters that possess 
reduce risk of insertional mutagenesis. 
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Introduction 
Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure disorder with pure 
red blood cell aplasia manifesting early in life. The hematological profile of DBA patients 
shows macrocytic anemia with reticulocytopenia, normal or decreased levels of neutrophils 
and variable platelets counts1. DBA patients also exhibit various non hematological 
manifestations such as physical abnormalities and cancer predisposition 2, 3.  
 In at least 60-70% of cases, DBA is caused by functional haploinsufficiency of genes 
encoding for ribosomal proteins 4, 5, 6, 7, 8, 9, 10, 11. Recent studies have discovered two novel 
genes, erythroid transcriptional factor GATA1 and TSR2, a direct binding partner of RPS26, 
can cause the DBA phenotype 35, 36, 37. Twenty-five percent of the patients have mutations in a 
gene coding ribosomal protein S19 (RPS19) 4. For given mutations all reported patients are 
heterozygous. Furthermore, in most of the cases the mutations are predicted to result in 
haploinsufficiency of the respective ribosomal protein 12, 13. Corticosteroids are the main 
therapeutic option in DBA 3.  Around 80% of the patients initially respond to corticosteroids, 
but only 40% of patients sustain the therapeutic response and the remaining 40% of patients 
need chronic blood transfusion. Twenty percent of the patients go into spontaneous remission 
and uphold acceptable hemoglobin level without therapeutic intervention. The only curative 
treatment available for DBA patients is allogeneic bone marrow transplantation 14. 
Our previous studies demonstrated that enforced expression of RPS19 improves the 
proliferation, erythroid colony-forming potential and differentiation of patient derived 
RPS19-deficient hematopoietic progenitor cells in vitro 15, 16. Moreover, RPS19 
overexpression enhances the engraftment and erythroid differentiation of patient-derived 
hematopoietic stem and progenitor cells when transplanted into immune-compromised mice 
17. Collectively these studies suggest that gene therapy may be a future therapeutic modality 
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in the treatment of RPS19-deficient DBA. In our proof of principle study, using lentiviral 
vectors harbouring the spleen focus-forming virus (SFFV) promoter a codon-optimized 
human RPS19 cDNA followed by IRES and GFP (SFFV-RPS19), we showed that the DBA 
phenotype of the of the Rps19-deficient mice can be successfully treated 18.  
In our current study, we are assessing the efficacy of clinically relevant promoters to drive the 
therapeutic gene. To this effect, we designed lentiviral vectors harboring a codon-optimized 
human RPS19 cDNA driven by the shortened version of human elongation factor 1α (EFS) 
promoter. Lentiviral vectors with EFS promoter have been shown to have a significantly 
decreased risk of insertional mutagenesis 27, 33  and no evidence of clonal dominance  were 
reported during clinical trials of gene therapy for SCID-X1 using EFS promoter 34. 
The EFS promoter is followed by IRES and GFP (EFS-RPS19), while a vector without the 
RPS19 cDNA was used as a control (EFS-Spacer). To assess the therapeutic potential of the 
EFS-RPS19 vector in vivo, we transduced c-Kit enriched bone marrow cells from control and 
uninduced shRNA-D mice were injected into lethally irradiated wild-type mice. The 
recipients transplanted with the EFS-Spacer transduced shRNA-D bone marrow showed a 
dramatic decrease in blood cellularity that led to death after a few weeks, while the recipients 
transduced with EFS-RPS19 shRNA-D bone marrow exhibited close to normal blood 
cellularity. These results demonstrate that the EFS promoter driven enforced expression of 
RPS19 can cure the severe anemia and bone marrow failure in RPS19 deficient mice.  
Results   
Enforced expression of RPS19 by the EFS promoter in Rps19 deficient bone marrow 
cells improves proliferation and erythroid development in vitro. 
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We have shown that enforced expression of RPS19 expands the erythroid development in 
RPS19-deficient DBA patients 15, 16, 17. In our previous study using lentiviral vectors driven 
by SFFV promoter, we showed that the DBA phenotype of the mice can be successfully 
treated 18. In this study we assessed the efficacy of clinically relevant promoters like the EFS 
promoter in our mouse model of RPS19 deficient DBA. Concisely, this model contains an 
Rps19- targeting shRNA (shRNA-D) that is expressed under a doxycycline-responsive 
promoter located downstream of the Collagen A1 gene (Figure 1A). Experimental animals 
were bred to be either heterozygous (D+) or homozygous (DD) for the shRNA in order to 
generate two models with intermediate or severe Rps19 deficiency, respectively (Figure 1B). 
To correct the Rps19 deficiency, we developed Self Inactivating (SIN) - lentiviral vectors 
harboring a codon-optimized human RPS19 cDNA driven by the internal EFS promoter, 
followed by IRES and GFP (EFS-RPS19) with or without a beta-globin locus control region 
(LCR) cassette (Figure 1C). The codon-optimized RPS19 cDNA was further modified to 
prevent its recognition and downregulation by the Rps19-targeting shRNA used. A similar 
vector without the RPS19 cDNA was used as a control vector (EFS-Spacer) 18, 20, 21, 22. 
In order to assess the functionality of these vectors, we cultured transduced c-Kit enriched 
BM cells from control and heterozygous RPS19 shRNA (D+) mice in liquid cultures in the 
presence of doxycycline (Figure 2A). Based on the percentage of GFP+ cells initial 
transduction efficiency were found to be on average between 20% and 40% (Figure 3C). The 
D+ cells transduced with the EFS-Spacer control vector failed to expand during 7 days of 
culture after transduction (Figure 2B). In contrast, the EFS-RPS19 and LCR-EFS-RPS19 
vectors mediated a 2-fold increase in total cell number when compared to the EFS-Spacer 
vector.  
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Next we quantified the erythroid colony forming potential of transduced c-Kit enriched BM 
cells from control and D+ mice in methyl cellulose cultures in the presence of doxycycline 
for 14 days (Figure 2 C). The findings demonstrate that the EFS-RPS19 and LCR-EFS-
RPS19 vectors mediated a 3-fold increase in total number of erythroid colonies when 
compared to the EFS-Spacer vector.  
Enforced expression of RPS19 by the EFS promoter is sufficient to rescue the DBA 
phenotype in vivo 
Subsequently, we probed whether EFS-RPS19 and LCR-EFS-RPS19 vectors generates 
sufficient amount of RPS19 in vivo in order to assay the therapeutic efficacy. Doxycycline 
administration to the transplanted recipients with homozygous RPS19 shRNA (DD) genotype 
causes acute and lethal bone marrow failure, while recipients with D+ (one RPS19 shRNA 
allele) develop a mild chronic anemia 22. Since the DD mice develop lethal bone marrow 
failure shortly after doxycycline administration we chose this model to test the efficacy of 
gene correction to rigorously test whether the lethal phenotype could be rescued and the mice 
cured. Un-induced bone marrow cells from the control and DD mice were transduced with 
the vectors, and the transduced cells were transplanted into wild-type recipient mice. 
Following engraftment and stable donor derived regeneration of the hematopoietic system, 
the recipient mice were administered doxycycline to downregulate the endogenous Rps19 in 
order to induce the disease (Figure 3A).  Since we have shown previously that the 
hematopoietic phenotype in Rps19-deficient mice is autonomous to the blood system, we 
decided to use lethally irradiated wild-type recipients 22.  
Before transplantation, initial transduction efficiencies with therapeutic and control vectors  
were measured based on the percentage of GFP+ cells and found to be on average between 
20% and 40% (Figure 3C). After two weeks of doxycycline treatment most of the mice 
	 7	
receiving DD bone marrow transduced with EFS-Spacer vector died due to dramatic bone 
marrow failure (data not shown). At this time point all groups showed high overall donor 
reconstitution confirming the absence of recipient-derived hematopoiesis (Figure 3D). We 
demonstrated that the recipients transplanted with the EFS-RPS19 or LCR-EFS-RPS19 DD 
bone marrow had normal blood cellularity (Figure 3E–F). 
Doxycycline administration for 18 weeks was used as time point to assess long term efficacy 
(Figure 4A). Most recipients with the DD bone marrow transduced with EFS-spacer vectors 
died but the remaining surviving recipients exhibited a decrease in erythrocyte numbers, 
hemoglobin value, platelet counts and showed macrocytic anemia (Figure 4B-H). 
Remarkably, the recipients transplanted with the EFS-RPS19 or LCR-EFS-RPS19 DD bone 
marrow had normal blood cellularity and bone marrow cellularity (Figure 4C-H). 
Additionally, we analyzed the samples by FACS to allow fractionation of the myeloid -
erythroid compartment in the bone marrow 22-23.  The mean percentage of GFP+ cells was 
substantially higher in the recipients with EFS-RPS19 or LCR-EFS-RPS19 DD bone marrow 
than in the other groups indicating the competitive advantage of gene-corrected cells in the 
hematopoietic hierarchy (Figure 5A-F).  
RPS19-deficient bone marrow cells transduced with RPS19 vectors provide long term 
reconstitution. 
We asked whether doxycycline induced Rps19-defcient bone marrow cells transduced with 
RPS19 lentiviral vectors can result in long-term engraftment in doxycycline induced lethally 
irradiated wild type recipient mice (Figure 6A). To this end, DD and control mice were 
induced with doxycycline for one week and erythrocyte numbers and hemoglobin levels were 
measured to confirm the DBA phenotype (Figure 6B-C). Bone marrow cells from induced 
mice were transduced and transplanted into doxycycline induced lethally irradiated mice. 
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Initial transduction efficiencies with therapeutic and control vectors were measured based on 
the percentage of GFP+ cells and found to be between 20% - 50% (Figure 6D). Most of the 
mice receiving DD bone marrow transduced with EFS-Spacer failed to engraft and did not 
survive beyond 2-3 weeks after transplantation. Almost 60% of the mice receiving DD bone 
marrow with corrected EFS-RPS19 vector survived and showed long term engraftment 
(Figure 6E). Long term engraftment and hematopoietic contribution of mice with gene 
corrected DD bone marrow was assessed at 16 week post transplantation. At this point these 
mice exhibited improved bone marrow cellularity and recovery of erythrocyte numbers, 
hemoglobin levels, and platelet counts (Figure 6F-K). 
Gene-corrected Rps19-deficient cells show polyclonal hematopoiesis and have a typical 
lentiviral insertion profile.  
A major apprehension regarding the future clinical use of lentiviral vector is the risk of 
insertional mutagenesis. In order to assess the safety of integration profile of the EFS-RPS19 
vector as well as clonal dynamics of the transduced cells, we performed insertion site analysis 
of DNA from bone marrow cells of four mice per vector group obtained from recipients after 
16-18 weeks of doxycycline administration. Integration sites per vector group (Wt-EFS-
Spacer = WES; Wt-.EFS-RPS19 = WER; Wt-LCR.-EFS-RPS19 = WLER; DD-EFS-RPS19 
=DER; DD-LCR-EFS.RPS19 = DLER) were analyzed by linear amplification mediated 
(LAM)-PCR followed by Ion Torrent sequencing. A total of 2.88 x106 sequences were 
processed, clustered for homology (increasing the read count of individual insertions), 
trimmed for remaining vector sequences and aligned to the murine genome. The 2.18 x105 
sequence reads were assigned to 5420 individual insertions. Despite the known limitations in 
terms of absolute quantification of amplicon sequencing in integration site analysis 24, we use 
the read count as a surrogate marker for clonal abundance. We investigated the insertion 
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profile in the different mice for the number of hits close to transcriptional start sites (TSS) of 
genes, the clonal diversity 25, common insertion sites (CIS) and overlaps with cancer gene 
databases. Detailed information for each mouse is provided in Supplementary Table 1 and 
Supplementary Figures 1-3. We did not observe a tendency to preferentially integrate within 
a 10 kb window around the TSS of genes (Figure 7A). The overlap of EFS-RP19 insertions 
with the retroviral tagged cancer gene database (RTCGD) 38 or the All Onco cancer gene list 
39 was not different from a randomized control dataset (Figure 7B).  We did not observe a 
significant difference in the clonal diversity between the vector groups. However, six mice 
had a lower sequence diversity (Supplementary Figure 2f) compared to all other treated 
animals. For two of these mice (DER1 and DLER3) we observed a dominant insertion within 
genes (Malt1 and Cdh26) listed in the RTCGD database. Both genes were found only once in 
an artificial B-cell lymphoma mouse model during insertional mutagenesis screens 26. From 
the overlap of gene symbols close to insertion sites and cancer gene databases alone, we 
cannot conclude a functional relationship between vector integration and increased clonal 
abundance. As we also cannot exclude a proliferation advantage due to insertional 
mutagenesis, we depict overlaps with 4 reference databases for those insertions with a read 
count above the 97.5%-tile of all reads (Supplementary Table 2) and for all detected CIS 
(Supplementary Table 3). A chi-square analysis revealed no statistical differences for the 
overlap with cancer gene databases between the vector groups. When we check for common 
high risk insertions in or near Prdm16, Mecom, Notch1, Lmo2, Setbp1, Ccnd2, Sox4, Tal1, 
we either found no hits (Lmo2, Tal1) or only read contributions ≤ 0.58% (n=19 out of 5420 
sequences). 
Discussion 
In this study we demonstrate the efficacy of RPS19 lentiviral vectors using clinically relevant 
promoters to correct the lethal bone marrow failure in Rps19 deficient mice. We showed that 
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the EFS promoter can express enough RPS19 to correct RPS19 deficient bone marrow failure 
and here for EFS driven RPS19 single gene vector can be used in a clinical gene therapy trial 
for RPS19 deficient DBA. Previously we already demonstrated that enforced expression of 
RPS19 improves the proliferation, erythroid colony-forming potential and differentiation of 
patient derived RPS19-deficient hematopoietic progenitor cells in vitro 15, 16. Using xenograft 
models we have also shown that overexpression of RPS19 enhances the engraftment and 
erythroid differentiation of patient-derived hematopoietic stem and progenitor cells 17. In our 
proof of principle study, using lentiviral vectors driven by the SFFV promoter, harboring a 
codon-optimized human RPS19 cDNA followed by IRES and GFP, we showed that the DBA 
phenotype of the mice can be successfully treated 18.  
In the current study we decided to utilize ubiquitously expressed EFS promoter with or 
without Locus control region (LCR) of beta globin gene for treatment of RPS19-deficient 
DBA. We have shown that these vectors rescue the proliferation defect and erythroid 
development of transduced c-Kit+ DD bone marrow cells in vitro. The induction of Rps19 
deficiency in recipient mice with the DD bone marrow generated lethal bone marrow failure. 
Remarkably, the bone marrow failure generated by DD bone marrow was cured with EFS-
RPS19. Since quite high levels of RPS19 are needed to correct the RPS19 deficiency by 
transgenesis, we were concerned that the EFS promoter might not generate sufficient levels 
of RPS19 in erythroid progenitors to correct the anemia. Therefore, we included vectors 
containing the EFS plus the beta globin locus control region. However, the findings show that 
the EFS promoter without the beta globin locus control region generates sufficient levels of 
RPS19 to cure the anemia and bone marrow failure in RPS19 deficient mice. 
Additionally, we demonstrated that RPS19-deficient bone marrow cells can be transduced 
and these cells survived the transduction procedure and had the capacity to repopulate the 
bone marrow. However, most of the studies were performed with transduced shRNAD/D 
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bone marrow and transplanted into normal recipients. The RPS19 deficiency was induced 
once the recipients had a stable graft. This is a justified since we have previously shown that 
the anemia and bone marrow failure in the induced mice is due to the deficiency in the 
hematopoietic cells and not due to a failure of the niche cells 22. If the recipients have Rps19 
deficiency in all cells before transplantation of the transduced cells, some of the Rps19 
deficient mice will not tolerate the combined toxicity of the doxycycline Rps19 
downregulation and the radiation. However, the majority of the Rps19 deficient mice 
survived this procedure as mentioned above. 
In this study, we have shown that our RPS19 deficient mouse model is a valuable and 
suitable model to test gene therapy using viral vectors with the RPS19 gene. It should 
however be emphasized that this model is different from the haploinsufficiency in DBA 
patinets which is based on mutations in the RPS19 gene, most often point mutations or small 
deletions. In the mice used here, the haploinsufficiency is generated by RNAi which is 
induced postnatally. The haploinsuficiency in the mice generates most of the hematological 
symptoms found in DBA but not the physical abnormalities found in a large fraction of 
patients. The haploinsufficiency in the mice causes reduced proliferation and erythroid 
development, which can be corrected by overexpression of RPS19. A similar effect was seen 
in cells from patients with RPS19 deficient DBA. Upon overexpression of RPS19 in these 
cells from patients, cellular proliferation and erythroid development were greatly improved 15, 
16. 
It is of course clear that the RPS19 vectors can only be used to treat patients with RPS19 
deficient DBA. Therefore, patients with mutations in other ribosomal protein genes or the 
GATA1 gene cannot be treated with RPS19 vectors. Recently, mutations in GATA1 were 
found in a few patients with DBA. The GATA1 gene in humans produces two mRNAs, a 
long one and a short one. The DBA patients could not produce the long form of GATA1 35. 
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Mice produce only the short form of GATA1 and it will therefore be difficult to evaluate the 
possibility of developing GATA1 gene therapy for GATA1 deficient DBA patients using 
mice as experimental animals. 
The data presented in Figure 5 shows that the RPS19 vectors increase the production of HSC 
and early progenitor cells after overexpression in RPS19 deficient hematopoietic cells. In 
competitive transplantation experiments, we showed previously that RPS19 deficient HSC 
have a competitive disadvantage compared to normal HSC 22. Collectively these data suggest 
that RPS19 deficient HSC treated with RPS19 vectors, may have a competitive advantage 
compared with untreated cells. It is therefore possible that gene therapy of RPS19 deficient 
DBA may be performed with little or no bone marrow ablation before transplantation of the 
gene corrected cells due to the possible competitive advantage of the gene corrected cells. 
However, the need for ablation in a clinical gene therapy setting needs to be investigated 
further in order to design clinical gene therapy trials with minimal risks for the patients. 
Significantly, by designing a codon-optimized RPS19 cDNA, driven by the EFS promoter, 
we have succeeded in generating a clinically relevant vector system that allows high enough 
RPS19 expression for functional correction of the anemia and BM failure in Rps19-deficient 
mice. Our studies assessing the efficacy of clinically relevant EFS promoters shows less 
likely risk to cause insertional oncogenesis 27. Further our studies using EFS-RPS19 or 
LCR.EFS-RPS19 vectors with these promoters are safer vectors that can generate sufficient 
RPS19 expression to correct the pathophysiology of Diamond Blackfan anemia. In normal 
cells, ribosomal protein production is tightly regulated physiological and excess protein is 
subjected to proteosomal degradation 28. Because of this mechanistic regulation of ribosomal 
protein, ectopic expression of RPS19 possesses a very low risk to promote uncontrolled 
growth.  In our study we did not observe any hematologic abnormalities due to enforced 
expression of RPS19. Our results collectively demonstrate the feasibility of clinical gene 
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therapy to cure RPS19-deficient DBA patients in the future using EFS promoter driven 
enforced expression of RPS19.  
Materials and Methods 
Lentiviral vector constructs 
Self-inactivating lentiviral vectors used in this study were derived from pRRL.PPT.PGK.GFP 
pre vector 19. A codon optimized human RPS19 cDNA was designed and inserted 
downstream of the Elongation factor 1a short (EFS) promoter with or without the locus 
control region of β-globin gene (LCR) 19, 20, 21.  Following the RPS19 cDNA, internal 
ribosomal entry site (IRES), GFP, and improved post transcriptional regulatory element 
(Pre*) were inserted. Two vectors were obtained without LCR 
pRRL.PPT.EFS.RPS19co.iresGFP.pre* vector (here after EFS-RPS19) and with LCR 
pRRL.PPT.LCR.EFS.RPS19co.iresGFP.pre* vector (here after LCR-EFS-RPS19). Lentiviral 
vectors were produced by the Vector Unit at Lund University. Briefly, standard calcium 
phosphate transfection of 293T cells was used with the helper plasmid pCMVΔR8.91 and 
pMDG. Lentivirus-containing supernatant was harvested 24 hours after transfection, and 
lentivirus was concentrated by ultrcentrifugation at 25000 rpm (SW32 rotor, Beckman L-70 
Ultracentrifuge) for 90 minutes at 4 ̊ C. pellets were resuspended in serum-free medium 
(StemSpan®SFEM, Stemcell technologies) and stored at -80 ̊ C. Lentivirus titer was assessed 
by FACS for the transfer of GFP to HT1080 cells. 
Mice  
The mouse models are engineered to contain a doxycycline-regulatable Rps19-targeting 
shRNA (shRNA-D) located downstream of the Collagen A1 locus allowing dose-dependent 
down regulation of Rps19 expression 22. Transgenic animals were bred either heterozygous or 
homozygous for the shRNA-D in order to generate two models with intermediate or severe 
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Rps19 deficiency, respectively. RPS19 deficiency was induced by feeding the mice with 
doxycycline in the drinking water (1 mg/ml or 2 mg/ml doxycycline; Sigma–Aldrich) 
supplemented with 10 mg/ml sucrose (Sigma–Aldrich). Mice were maintained at Lund 
University animal facility and all animal experiments were performed with consent from 
Lund University animal ethics committee. 
Blood and bone marrow analysis 
Peripheral blood was collected from the tail vein into microvette tubes (Sarstedt) and 
analyzed using sysmex XE-5000.  Erythrocytes were lysed using Ammonium chloride for 10 
minutes at room temperature. To evaluate the contribution towards various blood lineages 
following BM transplantation, samples were stained with the following antibodies for 30 
minutes on ice in the dark: CD45.1 (Biolegend, 110730) CD 45.2 (eBioscience, 47-0454-82), 
B220 (Biolegend, 103208), B220 (Biolegend, 103212), CD3 (Biolegend, 100312), CD11b 
(Biolegend, 101208), Gr1 (Biolegend, 108408). Experiments were performed using a FACS 
CantoTM II cytometer and analyzed by FlowJo software (Tree Star, v10.0.2). FACS analysis 
of the myeloerythroid compartment in BM was performed 22, 23. BM cells were isolated by 
crushing femur and tibia in PBS containing 2% FBS (GIBCO). Fresh cells were stained with 
antibodies: CD41 (eBioscience; 12-0411-83) GR1 (Biolegend; 115910), CD11b (Biolegend; 
101210), B220 (Biolegend; 103210), CD3 (Biolegend; 100310), c-Kit (eBioscience; 47-
1171-82), CD105 ((Biolegend; 120404) and Sca-1 (Biolegend; 122520). Streptavidin was 
purchased from Life Technologies (Q10101MP). Propidium iodite (Life Technologies) was 
used to exclude dead cells. Experiments were performed using FACS LSRTM II cytometer 
(Becton Dickinson) and analyzed by FlowJo software (Tree Star, v10.0.2).  
Transduction and transplantation of hematopoietic cells 
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C-Kit+ expressing cells were enriched from bone marrow of transgenic mice  (CD45.2) using 
CD117 microbeads and MACS separation column (Miltenyi) and pre – stimulated in serum-
free StemSpan®SFEM medium (Stemcell technologies) supplemented with 
penicillin/streptomycin (P/S; GIBCO), mSCF (100ng/ml, PerproTech), human 
Thrombopoietin (hTPO; 50ng/ml , PerproTech) in 6-well plates (non-tissue culture treated; 
BD) for 1 day 0.5*106 cells per ml. Retronectin-coated  (20ng/ml; Takara) 6 well plates were 
preloaded with the viral vectors (100 ul per well  corresponding to MOI of 10-20) and one 
million cells were seeded into each well in 3 ml pre stimulation medium. After incubation for 
one day, 0.5*106 bulk transduced cells were transplanted in 500 ul PBS into tail vein of 
irradiated mouse (900cGy) wild type recipients (CD45.1 or CD45.1/45.2). 
Transduction and transplantation of RPS19 deficient hematopoietic cells 
 Lineage negative (Lin-) cells were enriched from the bone marrow of the doxycycline 
induced transgenic mice (CD45.2) using Lineage microbeads and MACS separation column 
(Miltenyi). Retronectin-coated  (20ng/ml; Takara) 6 well plates were preloaded with the viral 
vectors (100 ul per well  corresponding to MOI of 10-20) and one million cells were seeded 
into each well in 3 ml of serum-free StemSpan®SFEM medium supplemented with P/S, 
mSCF (100ng/ml), hTPO (50ng/ml) , doxycycline (1ug/ml, Sigma–Aldrich) in 6-well plates 
(non-tissue culture treated; BD) for one day 0.5*106 cells per ml. After incubation for one 
day, 0.5*106 bulk transduced cells and 1*106 of untransduced Lin+ cells were in 300 ul PBS 
transplanted into tail vein of lethally irradiated mouse (900cGy) wild type recipients (CD45.1 
or CD45.1/45.2). 
Cell culture  
C-Kit+ expressing cells were enriched using CD117 microbeads and MACS separation 
column (Miltenyi) and Retronectin-coated  20ng/ml; Takara) pre – stimulated in serum-free 
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StemSpan®SFEM medium supplemented with P/S, mSCF (100ng/ml), hTPO (50ng/ml) in 6-
well plates (non-tissue culture treated; BD) for 1 day 0.5*106 cells per ml. 12 well plates were 
preloaded with the viral vectors (50 ul per well  corresponding to MOI of 10-20) and 0.5*106 
cells were seeded into each well in 1 ml cultured in serum-free StemSpan®SFEM medium 
supplemented with P/S, mSCF (100ng/ml), murine IL3 (mIL3; 10 ng/ml; PeproTech), 
Erythropoietin (EPO; 2U/ml; Janssen-Cilag) with or without Doxycycline (1ug/ml). Light 
microscope was used to evaluate the proliferation of culture after 6 days. For BFU-E assay, 
40*103 c-Kit+ transduced cells were seeded in 1.5ml of M3436 methylcellulose (StemCell 
Technologies) with doxycycline (1ug/ml) and colonies were scored on Day 14. 
Insertion site analysis 
We used 300 ng genomic DNA of whole bone marrow cells, isolated 18 weeks after 
transplantation. Samples were processed by linear amplification mediated (LAM)-PCR as 
described by Schmidt and colleagues with modifications 29. For digestion, samples were split 
into three separate reactions with 5 units of CutSmart enzymes MlucI, MseI and HindPI 
(latter two with heat inactivation) from NEB (Ipswich, MA, USA). After digestion, samples 
were combined for nested PCR steps. The first nested PCR was performed with a forward 
primer binding to the SIN-LTR of the vectors (IT-IS-FW-PCR1: 5’- 
GTGGGTTTTCCAGTCACACTGCTCTTCCGATCTTCCCTCAGACCCTTTTAGTCA-3’) 
and reverse primer recognizing the linker cassette (IT-IS-RV-PCR1: 5’-
TTCGTTGGGAGTGAATTAGCC AGTGGCACAGCAGTTAGG-3’). The vector and linker 
specific sequences are underlined, the italic sequence represents a tail homologous to the 
primers used for Ion Torrent sequencing, as described previously 30. Bioinformatics 
processing with custom Perl, R and visual basic scripts involved barcode primer assignment, 
trimming, clustering, filtering and MAVRIC alignment 31. For common insertion site (CIS) 
analysis, we followed the suggestions by Wu et al., considering only 5 or more insertions in a 
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50kb window 32. The distance to the transcriptional start sites was analyzed using the 
information of the MAVRIC alignments in combination with a customized R script (ggplot2; 
geom_histogram with parameters aes y = density and binwidth 1000). 
Control datasets for integration site analysis 
The gamma retroviral integrations used for comparison, originate from lineage negative cell 
cultures (n = 4) transduced with RSF91 40 41. DNA was harvested four days after 
transduction. LAM-PCR procedure and next generation sequencing as described above. The 
randomized control datasets (n=3) were produced by generating artificial chromosomal 
positions using the shuffle command (seed = 100, 101 and 102) of BEDtools 42. The shuffled 
BED files contained 2000 genomic positions (500 bp window size) randomly distributed 
among the murine genome (NCBI47/mm9) as a function of the chromosome size. The BED 
files were converted to FASTA format and processed by MAVRIC with identical parameters 
as to the biological insertion site data of EFS-RPS19 or the gamma retroviral vector. 
 Statistical analysis 
One-way ANOVA with Tukey’s multiple-comparison test was used to determine statistical 
significance using GraphPad Prism Version 6 (GraphPad software). 
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Figure Legends 
Figure 1: Mouse model for RPS-deficient DBA and SIN Lentiviral vectors for DBA gene 
therapy 
Transgenic mice containing a doxycycline-regulatable Rps19-targeting shRNA allow an 
inducible and graded downregulation of Rps19. (A) Overview of modified loci. (SA, splice 
acceptor; pA, polyadenylation signal. Black arrowheads in (A) indicate transcriptional start 
sites). (B) Breeding strategy to adjust the level of Rps19 downregulation.  (C) EFS-RPS19 
vector, codon-optimized human RPS19 cDNA was constructed under the control of the 
human elongation factor 1a short (EFS) promoter and inserted into a lentiviral vector. 
Following the RPS19 cDNA, an internal ribosomal entry site (IRES), a green fluorescent 
protein (GFP) sequence, and improved posttranscriptional regulatory element (Pre*) were 
inserted to form the (D) EFS-Spacer vector, in which the RPS19 cDNA was replaced with an 
equally long non-coding spacer sequence, was used as a control. (E) The LCR-EFS-RPS19 
vector, where in Locus control region of Beta globin gene was inserted before the EFS 
promoter.  
Figure 2: Enforced expression of RPS19 derived from the EFS promoter is sufficient to 
rescue the DBA phenotype in vitro. 
C-Kit-enriched hematopoietic progenitors (0.5*106) from the bone marrow of un-induced 
mice were transduced and seeded in liquid culture or methyl cellulose in presence of 
doxycycline. (A) Experimental design. (B) Total cell counts on day 8 after growth in liquid 
culture. (C) Total erythroid colony counts in methyl cellulose cultures (M3436) in the 
presence of doxycyline on day 14. Data shown in (B) and (C) represent the average of three 
independent experiments with three technical replicates. P<0.05 = *, P<0.001 = ***. 
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Figure 3: Enforced expression of RPS19 derived from the EFS promoter is sufficient to 
rescue the acute DBA phenotype in vivo. 
Enforced expression of RPS19 results in short-term rescue of the hematological defect of 
RPS19-deficient mice. (A) Experimental strategy to validate the short-term therapeutic 
potential of EFS-RPS19 and LCR-EFS-RPS19 vectors. (B) Transduction efficiency (C-D) 
GFP reconstitution and donor reconstitution (E-G) Erythrocytes number, hemoglobin 
concentration, mean corpuscular value (MCV) (n=20-21).  Error bars represents standard 
deviation. P<0.001 = ***. 
Figure 4: Enforced expression of RPS19 derived from the EFS promoter is sufficient to 
rescue the DBA phenotype in vivo. 
Enforced expression of RPS19 results in long-term rescue of the hematological defect of 
RPS19-deficient mice. (A) Experimental strategy to validate the long-term therapeutic 
potential of EFS-RPS19 and LCR-EFS-RPS19 vectors. (B) Survival curve, (C) Bone marrow 
cellularity after 18 weeks of doxycycline induction. (D-H) Erythrocytes number, hemoglobin 
concentration, mean corpuscular value (MCV), White blood cell count and Platelet number 
after 18 weeks of doxycycline induction. (n=20-21).  Error bars represents standard deviation. 
P<0.05 = *, P<0.01 = **, P<0.001 = ***. 
Figure 5: Gene-corrected Rps19-deficient cells gain a competitive advantage resulting in 
increased contribution to hematopoiesis in vivo. 
The percentage of transduced cells in the (A) hematopoietic stem cell (B) MkP (C) pre GM 
and GMP (C) preMegE (D) preCFU-E  and CFU-E (E) erythroblast compartment  (n = 16-24 
per group) Error bars represents standard deviation. P<0.05 = *, P<0.01 = **, P<0.001 = ***. 
Figure 6: Rps19-deficient BM cells can be transduced and the transduced cells provide 
long term reconstitution. 
	 26	
Rps19 deficient bone marrow can be transduced and after genetic correction these show long 
term engraftment in lethally irradiated wild type mice. (A) Experimental strategy to validate 
the long-term reconstitution capacity of corrected Rps19-deficient cells. (B) Pre transplant Wt 
and DD mice erythrocytes number and (C) hemoglobin concentration, (D) Transduction 
efficiency,   (E) Survival curve, (F) Bone marrow cellularity after 16 weeks of doxycycline 
induction. (G-K) Erythrocytes number, mean corpuscular volume (MCV), hemoglobin 
concentration, white blood cell count and platelet number after 16 weeks of doxycycline 
induction. (n=20-28).  Error bars represents standard deviation. P<0.05 = *,  P<0.01 = **, 
P<0.001 = ***.  
Figure 7: EFS-RPS19 integrations do not cluster around the TSS and show no increased 
overlap with cancer gene databases. 
(A) Density plot showing the frequency of integrations in a 10 kb window around the 
transcriptional start site (TSS). As we found no statistical differences between the different 
EFS-RPS19 vectors, we combined them in one group (blue) and compared them to a gamma 
retroviral integration profile (red) or a randomized dataset (grey). (B) The overlap of gene 
symbols closest to the insertion sites with either the retroviral tagged cancer gene database 
(RTCGD) or the AllOnco cancer gene list of the EFS-RPS19 vectors was not different from 
that of a randomized dataset. The increased overlap of gamma retroviral integration dataset is 
shown for comparison. 
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transcriptional start site (TSS) of a gene and the combined TSS information (c). Percent
of intronic sequences found (d). The Shannon diversity index for the different vector
groups (e).  Shannon indices of all individual animals (f). Animals above the  95%
confidence interval (CI) are marked in blue, those with a lower index in red. In a-e, bars
indicate means +/- SD. In f, the bar indicates the mean together with the upper and lower
95%-CI.
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1 35.66% Nedd4l 66.86% Spag16 55.67% G m 8910 48.54% B3gnt2
2 15.28% Spock1 6.15% Tssc1 17.42% Sﬁ1 21.08% Arhgap21
3 6.48% Prdm11 3.02% Pecam1 6.22% 1810012P15Rik 8.21% Nr2f1
4 6.38% Gse1 2.67% Cpeb3 3.71% Atp2b2 2.23% Fc hs d2
5 3.06% Smo 2.38% Fggy 1.99% G m 8910 1.44% Pth1r
6 2.45% Zhx2 1.42% A330033J07Rik 1.42% Cand1 1.08% Slitrk3
7 0.83% Map4k2 1.27% Clstn2 0.98% G tf3c 1 1.06% Fos
8 0.72% Ckap2l 1.15% Tmem86a 0.73% Cand1 0.62% Dpyd
9 0.71% Stk4 0.88% Acyp2 0.72% Aﬀ3 0.58% Fam171a1
10 0.69% Ttc23l 0.82% En1 0.71% Gm5045 0.55% Cdh13
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1 26.08% Cdh23 92.28% Clasp2 58.35% Asb5 79.43% Clasp2
2 16.24% Wwox 4.29% Plxdc2 6.65% Prkca 6.88% Shroom3
3 7.22% Sult4a1 1.38% Veph1 3.73% Pik3c3 1.64% Brpf1
4 7.03% Zfp516 0.78% Gm2382 2.33% Foxi3 1.10% Hspg2
5 5.98% Dhx15 0.21% Pdha2 2.03% Palld 0.87% Ptbp2
6 3.55% Txlng 0.13% Tbcd 1.89% Hspg2 0.72% Arhgap21
7 3.01% Rpap3 0.11% Supt3h 1.66% Zik1 0.51% Steap4
8 2.63% Hmgcs2 0.05% 2810021B07Rik 0.97% Satb2 0.45% Pvrl1
9 2.47% March1 0.04% Cd9 0.97% Otof 0.38% Ahr
10 0.98% Sgms1 0.03% C130026I21Rik 0.92% Prim2 0.32% Timp2
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# % Reads Gene Symbol % Reads Gene Symbol % Reads Gene Symbol % Reads Gene Symbol
1 74.72% Malt1 55.65% Ogfrl1 78.25% Olig3 27.99% S lc 35b4
2 12.84% Rbbp4 17.83% Mta3 11.89% Il21r 14.39% Maml2
3 4.26% Phip 4.66% R� 3.31% Olfr417 7.15% Pcca
4 2.67% 2700078E11Rik 3.18% Tbl1xr1 0.99% Ephb2 6.14% Ndrg4
5 0.57% Tshz2 2.91% S lc 35b4 0.80% Lao1 5.05% Cd37
6 0.49% Mixl1 2.45% 4833422C13Rik 0.74% Hdac2 2.33% Tkt
7 0.49% Il21r 1.33% Gcap14 0.39% Cd36 1.63% Cyp26b1
8 0.36% Diap3 0.69% Speer7-ps1 0.33% Etl4 1.56% 1700018B08Rik
9 0.31% Chuk 0.63% Pnliprp2 0.26% Ankrd28 1.48% Sgk1
10 0.23% 5730507C01Rik 0.43% Nkx1-1 0.20% Tkt 1.32% Kcnt2
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# % Reads Gene Symbol % Reads Gene Symbol % Reads Gene Symbol % Reads Gene Symbol
1 42.88% Cd81 42.53% Plekhb1 89.99% Cdh26 41.39% Cebpe
2 13.53% Cdh13 16.98% Slco4c1 2.02% Mier1 10.38% 4932443L11Rik
3 10.97% G tf3c 1 6.53% Pkd2l2 0.90% C1galt1 9.62% Cd93
4 5.01% Stk40 4.63% Tpm1 0.67% Mrgprg 5.99% Eya1
5 4.00% Adam32 3.46% Raph1 0.67% Dok5 4.39% Aadacl3
6 3.19% 1700030K09Rik 2.89% Lsamp 0.56% Eya1 4.31% Ndufaf3
7 3.15% 4932443L11Rik 1.27% Fzd6 0.45% Pappa 1.70% Pxn
8 1.91% Bad 1.13% Fhit 0.45% Tbcb 1.61% Glul
9 1.18% Gm17019 1.09% Fat3 0.34% Itgb5 1.60% Gal3st4
10 1.17% Lamb1 1.06% 1700056E22Rik 0.34% Grid1 1.40% Mark2
DLER1 DLER2 DLER3 DLER4
The genes of the top 10 contributing sequences (in %) are shown for each animal. The bar graphs
on the right display this composition as stacked frequencies. The color code of the bars corresponds
to the color code of the numbers (#) in the respective tables (grey indicate the sum of all other
sequences).  Gene symbols are colored in case they were found more than once.
Supplementary Figure 3
Supplementary Table 1 - Sequence statistics
Individual sequencing results:
Animal Vector Group BC
Sequences 
allocated to BC
Carrying a 
full LTR
Carrying a 
full Linker
After internal 
control removal
Aligned 
sequences 
using MAVRIC
Individual 
Sequences
SeqIDs
>97.5%-tile
- 10 kb to 
TSS in %
+ 10 kb to 
TSS in %
+/- 10 kb to 
TSS in %
Mean TSS
Distance (kb)
% of intronic 
insertions 
(closest)
% of 
intronic 
insertions
H'-Shannon
diversity 
index
% GFP 
positive 
preTX
% GFP 
positive
18 weeks
RTCGD
overlap
closest
AllOnco
overlap
closest
WES1 Wt.EFS.Spacer 1 105494 103740 65022 63553 2069 398 10 7.5% 10.3% 17.8% 91 31.66% 47.74% 4.06 23.50% 5.14% 21.5% 11.8%
WES2 Wt.EFS.Spacer 2 100350 99502 37108 35724 764 282 8 9.2% 16.0% 25.2% 83 37.59% 54.26% 4.65 25.10% 13.10% 20.0% 14.7%
WES3 Wt.EFS.Spacer 3 120633 116954 73715 72065 13866 424 11 6.6% 10.6% 17.2% 103 32.78% 46.93% 1.50 25.10% 12.60% 19.4% 13.5%
WES4 Wt.EFS.Spacer 4 112974 111675 62595 61028 4684 428 11 9.6% 10.7% 20.3% 106 28.27% 44.16% 3.19 11.40% 11.50% 20.5% 12.1%
WER1 Wt.EFS.RPS19 5 129681 127154 64593 63197 3159 340 9 7.9% 11.8% 19.7% 72 33.53% 55.29% 3.28 45.40% 19.40% 16.7% 12.8%
WER2 Wt.EFS.RPS19 6 130555 128646 84691 83221 50704 177 5 11.3% 8.5% 19.8% 79 32.77% 51.98% 0.41 32.00% 32.30% 20.8% 11.9%
WER3 Wt.EFS.RPS19 7 109192 106162 61024 59096 6494 356 9 7.6% 11.2% 18.8% 109 33.71% 52.81% 2.39 38.30% 17.60% 21.0% 12.1%
WER4 Wt.EFS.RPS19 8 148872 147339 65164 63243 10748 334 9 8.7% 14.4% 23.1% 63 39.22% 59.88% 1.25 42.10% 4.90% 20.7% 11.0%
WLER1 Wt.LCR.EFS.RPS19 11 128438 127783 24884 23013 7224 497 13 12.9% 17.1% 30.0% 61 34.41% 56.54% 3.24 11.80% 15.20% 19.8% 11.6%
WLER2 Wt.LCR.EFS.RPS19 12 113195 110689 43684 42894 6843 235 6 7.7% 10.6% 18.3% 92 30.64% 48.09% 1.90 68.90% 15.20% 18.0% 13.4%
WLER3 Wt.LCR.EFS.RPS19 21 139277 134936 63442 61599 8197 248 7 6.9% 15.7% 22.6% 84 33.87% 47.98% 1.94 68.90% 59.30% 23.4% 11.3%
WLER4 Wt.LCR.EFS.RPS19 22 161499 156489 41953 40783 4520 291 8 10.7% 12.7% 23.4% 103 34.71% 56.01% 2.26 23.70% 17.40% 19.0% 8.9%
DER1 DD.EFS.RPS19 13 148907 144519 102312 101976 11484 145 4 10.3% 9.0% 19.3% 86 34.48% 55.86% 1.08 43.50% 76.20% 17.1% 11.6%
DER2 DD.EFS.RPS19 14 138631 135513 46789 44767 15308 81 2 6.2% 16.0% 22.2% 87 35.80% 59.26% 1.85 40.60% 71.60% 20.3% 12.2%
DER3 DD.EFS.RPS19 23 128768 124575 63485 60339 41511 298 8 8.4% 11.7% 20.1% 85 29.87% 49.33% 0.98 40.60% 60.80% 16.4% 11.6%
DER4 DD.EFS.RPS19 24 274024 265305 109004 108042 1286 172 5 7.6% 16.3% 23.8% 78 37.79% 59.30% 3.32 40.20% 71.40% 20.9% 12.9%
DLER1 DD.LCR.EFS.RPS19 15 268150 265875 59078 57761 16021 218 6 9.2% 12.4% 21.6% 72 40.37% 59.17% 2.41 10.00% 68.90% 19.1% 8.8%
DLER2 DD.LCR.EFS.RPS19 16 144241 142428 45056 44413 4423 244 7 5.7% 7.0% 12.7% 116 36.07% 48.36% 2.59 68.10% 63.80% 18.8% 11.9%
DLER3 DD.LCR.EFS.RPS19 17 155660 150682 122317 122181 889 35 1 8.6% 14.3% 22.9% 106 28.57% 51.43% 0.63 68.10% 88.90% 17.6% 2.9%
DLER4 DD.LCR.EFS.RPS19 18 117431 116347 34094 33351 8137 217 6 11.5% 16.6% 28.1% 53 31.34% 57.14% 2.66 22.90% 56.90% 22.7% 11.1%
Mean values for the individual groups:
Animal Vector Group BC
Sequences 
allocated to BC
Carrying a 
full LTR
Carrying a 
full Linker
After internal 
control removal
Aligned 
sequences 
using MAVRIC
Individual 
Sequences
SeqIDs
>97.5%-tile
- 10 kb to 
TSS in %
+ 10 kb to 
TSS in %
+/- 10 kb to 
TSS in %
Mean TSS
Distance (kb)
% of intronic 
insertions 
(closest)
% of 
intronic 
insertions
H'-Shannon
diversity 
index
% GFP 
positive 
preTX
% GFP 
positive
18 weeks
RTCGD
overlap %
closest
AllOnco
overlap %
closest
WES1-4 Wt.EFS.Spacer - 1.10E+05 1.08E+05 5.96E+04 5.81E+04 5346 383 10 8.2% 11.9% 20.1% 96 32.6% 48.3% 3.35 21.3% 10.6% 20.3% 13.0%
WER1-4 Wt.EFS.RPS19 - 1.30E+05 1.27E+05 6.89E+04 6.72E+04 17776 302 8 8.9% 11.5% 20.3% 91 34.8% 55.0% 1.83 39.5% 18.6% 19.8% 12.0%
WLER1-4 Wt.LCR.EFS.RPS19 - 1.36E+05 1.32E+05 4.35E+04 4.21E+04 6696 318 9 9.5% 14.0% 23.6% 90 33.4% 52.2% 2.34 43.3% 26.8% 20.0% 11.3%
DER1-4 DD.EFS.RPS19 - 1.73E+05 1.67E+05 8.04E+04 7.88E+04 17397 174 5 8.1% 13.3% 21.4% 91 34.5% 55.9% 1.81 41.2% 70.0% 18.7% 12.1%
DLER1-4 DD.LCR.EFS.RPS19 - 1.71E+05 1.69E+05 6.51E+04 6.44E+04 7368 179 5 8.8% 12.6% 21.3% 81 34.1% 54.0% 2.08 42.3% 69.6% 19.6% 8.7%
Abbreviations and explanation of special terms: 
Animals 1-4 = WES for Wt.EFS.Spacer; WER = Wt.EFS.RPS19; WLER = Wt.LCR.EFS.RPS19; DER = DD.EFS.RPS19; DLER = DD.LCR.EFS.RPS19. 
BC = Barcode primer ID; LTR = Long terminal repeat; internal control = vector specific amplicon generated for all samples due to primer extension from the LTR into the vector; MAVRIC = alignment tool available at http://mavric.erasmusmc.nl;  
SeqIDs >97.5%-tile = The read count for all individual sequences which belonged to a specific barcode primer were used determine the 97.5% as a cutoff to identify statisitcally dominant sequences; kb = kilo base pairs; TSS = transcriptional start 
site. 
Sequence BC
Gene 
Symbol
Reads Reads % Chr.
Raw
Distance
TSS
Distance
RTCGD NCG Bushman Deichmann Vector
SeqID586509 13 Malt1 8201 74.73% 18 intronic 11974 1 DD.EFS.RPS19
SeqID4205569 13 Rbbp4 314 12.85% 4 intronic 7647 DD.EFS.RPS19
SeqID2713415 13 2700078E11Rik 290 2.67% 19 intronic 31910 DD.EFS.RPS19
SeqID4252778 13 Phip 256 4.26% 9 intronic 27925 DD.EFS.RPS19
SeqID3565639 14 Ogfrl1 8181 55.65% 1 -14065 -14113 DD.EFS.RPS19
SeqID43762 14 Mta3 2032 17.83% 17 intronic 29885 3 DD.EFS.RPS19
SeqID1949000 23 Olig3 32483 78.25% 10 25772 -25822 DD.EFS.RPS19
SeqID1108949 23 Il21r 4385 11.89% 7 intronic 19608 DD.EFS.RPS19
SeqID5573409 23 Olfr417 1290 3.31% 1 12308 -12488 DD.EFS.RPS19
SeqID1184833 23 4930549C01Rik 409 0.99% 4 102741 105531 DD.EFS.RPS19
SeqID4697585 23 Lao1 327 0.80% 4 intronic 6412 DD.EFS.RPS19
SeqID4176892 23 Hdac2 307 0.74% 10 17354 -17383 DD.EFS.RPS19
SeqID6111976 23 Arhgap21 135 0.33% 2 -221609 342572 1 DD.EFS.RPS19
SeqID1486607 23 Cd36 120 0.39% 5 intronic 55201 DD.EFS.RPS19
SeqID4384655 24 Slc35b4 342 28.02% 6 -5909 -5970 DD.EFS.RPS19
SeqID4894480 24 Maml2 168 14.40% 9 21345 -21409 DD.EFS.RPS19
SeqID174802 24 4930594M22Rik 91 7.16% 14 185058 -185224 DD.EFS.RPS19
SeqID1545991 24 Ndrg4 78 6.15% 8 intronic 22298 DD.EFS.RPS19
SeqID4687807 24 Cd37 17 5.06% 7 -9747 -9785 3 DD.EFS.RPS19
SeqID4473143 15 Cd81 6693 42.88% 7 intronic 8627 DD.LCR.EFS.RPS19
SeqID4473143 15 Kcnq1 6693 42.88% 7 45823 -45888 DD.LCR.EFS.RPS19
SeqID1076133 15 Hsbp1 2160 13.53% 8 30307 -30347 DD.LCR.EFS.RPS19
SeqID164608 15 Gtf3c1 1758 10.97% 7 intronic 1501 DD.LCR.EFS.RPS19
SeqID6687017 15 Stk40 719 5.01% 4 intronic 26671 DD.LCR.EFS.RPS19
SeqID4031797 15 Adam32 641 4.00% 8 intronic 19399 DD.LCR.EFS.RPS19
SeqID2354018 15 1700030K09Rik 509 3.19% 8 intronic 14892 DD.LCR.EFS.RPS19
SeqID2354018 15 Eps15l1 509 3.19% 8 -37297 -37359 5 DD.LCR.EFS.RPS19
SeqID3289489 16 Plekhb1 1830 42.54% 7 -1214 -1271 3 DD.LCR.EFS.RPS19
SeqID1061386 16 Slco4c1 677 16.98% 1 -83376 136764 DD.LCR.EFS.RPS19
SeqID4056926 16 Pkd2l2 278 6.54% 18 intronic 23860 1 DD.LCR.EFS.RPS19
SeqID4885305 16 Tpm1 205 4.64% 9 intronic 7085 DD.LCR.EFS.RPS19
SeqID4920862 16 Raph1 147 3.46% 1 -35284 -35319 DD.LCR.EFS.RPS19
SeqID4120201 16 Gap43 115 2.89% 16 -239253 331463 DD.LCR.EFS.RPS19
SeqID3430700 16 Fzd6 56 1.27% 15 intronic 13874 DD.LCR.EFS.RPS19
SeqID3281443 17 Cdh26 800 90.09% 2 intronic 30063 1 DD.LCR.EFS.RPS19
SeqID6464552 18 Cebpe 3272 41.40% 14 -4779 6591 2 DD.LCR.EFS.RPS19
SeqID6464552 18 Acin1 3272 41.40% 14 -18568 -18652 DD.LCR.EFS.RPS19
SeqID4445526 18 4932443L11Rik 845 10.39% 8 intronic 13914 DD.LCR.EFS.RPS19
SeqID4445526 18 Evi5l 845 10.39% 8 intronic 26328 DD.LCR.EFS.RPS19
SeqID4445526 18 Lrrc8e 845 10.39% 8 33858 -33932 DD.LCR.EFS.RPS19
SeqID4445526 18 Map2k7 845 10.39% 8 45771 -45845 DD.LCR.EFS.RPS19
SeqID4258572 18 Cd93 739 9.62% 2 intronic 6570 DD.LCR.EFS.RPS19
SeqID4258572 18 Sstr4 739 9.62% 2 36305 41432 1 DD.LCR.EFS.RPS19
SeqID4956240 18 Eya1 430 5.99% 1 intronic 9140 1 DD.LCR.EFS.RPS19
SeqID6124805 18 Ndufaf3 345 4.31% 9 overlapping 1371 DD.LCR.EFS.RPS19
SeqID6124805 18 Dalrd3 345 4.31% 9 3920 -4053 2 DD.LCR.EFS.RPS19
SeqID573864 18 Aadacl3 325 4.39% 4 intronic 8110 DD.LCR.EFS.RPS19
SeqID3132051 5 Gm17455 824 26.09% 10 79572 83403 Wt.EFS.RPS19
SeqID4932493 5 Wwox 394 16.24% 8 intronic 131044 1 Wt.EFS.RPS19
SeqID1029546 5 Sult4a1 227 7.22% 15 intronic 8265 Wt.EFS.RPS19
SeqID4376068 5 Zfp516 222 7.03% 18 intronic 39408 1 Wt.EFS.RPS19
SeqID2637860 5 Dhx15 189 5.98% 5 intronic 36506 Wt.EFS.RPS19
SeqID5006758 5 Txlng 111 3.55% X intronic 8747 Wt.EFS.RPS19
SeqID4077725 5 Rpap3 95 3.01% 15 -77810 108528 Wt.EFS.RPS19
SeqID5028364 5 Hmgcs2 83 2.63% 3 intronic 15678 Wt.EFS.RPS19
SeqID2028512 5 March1 78 2.47% 8 203902 -203928 2 Wt.EFS.RPS19
SeqID1374495 6 Clasp2 31008 92.28% 9 intronic 29869 Wt.EFS.RPS19
SeqID6200104 6 Plxdc2 2176 4.29% 2 intronic 301285 1 Wt.EFS.RPS19
SeqID1350306 6 Veph1 504 1.38% 3 -8438 -8528 1 Wt.EFS.RPS19
SeqID3286496 6 Gm2382 396 0.78% 9 intronic 7111 Wt.EFS.RPS19
SeqID4583289 6 Pdha2 104 0.21% 3 -4512 6864 Wt.EFS.RPS19
SeqID1853950 7 Asb5 3330 58.36% 8 206019 -206043 Wt.EFS.RPS19
SeqID5725894 7 Prkca 409 6.65% 11 intronic 13088 1 Wt.EFS.RPS19
SeqID3892214 7 Pik3c3 223 3.73% 18 intronic 71794 Wt.EFS.RPS19
SeqID2917855 7 Foxi3 136 2.33% 6 69285 73821 Wt.EFS.RPS19
SeqID615467 7 Ldlrad2 123 1.89% 4 -20192 23960 Wt.EFS.RPS19
SeqID615467 7 Usp48 123 1.89% 4 43071 -43115 Wt.EFS.RPS19
SeqID3108392 7 4930512H18Rik 120 2.03% 8 7101 -7232 Wt.EFS.RPS19
SeqID4207183 7 Satb2 63 0.97% 1 intronic 13 Wt.EFS.RPS19
SeqID6083448 7 Otof 63 0.97% 5 intronic 61137 Wt.EFS.RPS19
SeqID5142031 7 Zik1 57 1.66% 7 intronic 5762 Wt.EFS.RPS19
SeqID2937544 8 Clasp2 8537 79.44% 9 intronic 29959 Wt.EFS.RPS19
SeqID3393560 8 Shroom3 739 6.88% 5 intronic 13551 Wt.EFS.RPS19
SeqID3306329 8 Brpf1 176 1.64% 6 intronic 996 Wt.EFS.RPS19
SeqID3020552 8 Ldlrad2 118 1.10% 4 -20152 23920 Wt.EFS.RPS19
SeqID3020552 8 Usp48 118 1.10% 4 43031 -43138 Wt.EFS.RPS19
SeqID2939831 8 Ptbp2 94 0.87% 3 -185892 -186085 Wt.EFS.RPS19
SeqID5421272 8 Steap4 51 0.51% 5 109606 -109690 Wt.EFS.RPS19
SeqID5721195 8 Pvrl1 47 0.45% 9 25889 -25920 Wt.EFS.RPS19
SeqID4441213 8 Arhgap21 43 0.72% 2 -19542 140505 1 Wt.EFS.RPS19
SeqID4985045 8 Ahr 36 0.38% 12 -159796 -159889 Wt.EFS.RPS19
SeqID2421234 1 Zfp869 358 17.31% 8 -13765 -13798 Wt.EFS.Spacer
SeqID1000377 1 Gm13498 175 11.56% 2 1925 4091 Wt.EFS.Spacer
SeqID1211330 1 Aicda 168 8.32% 6 11908 22288 Wt.EFS.Spacer
SeqID1211330 1 Apobec1 168 8.32% 6 -1629 26282 Wt.EFS.Spacer
SeqID2326942 1 Pigy 89 4.50% 6 -39374 44877 Wt.EFS.Spacer
SeqID6572120 1 Slc41a2 77 3.72% 10 intronic 38093 Wt.EFS.Spacer
SeqID6322744 1 Golim4 61 5.85% 3 -7726 -7765 Wt.EFS.Spacer
SeqID3991195 1 Wnt2 55 2.66% 6 -41048 82694 Wt.EFS.Spacer
SeqID3340846 1 Lepre1 40 1.93% 4 intronic 1615 Wt.EFS.Spacer
SeqID2492575 1 2700046G09Rik 31 2.80% 19 151477 -151558 Wt.EFS.Spacer
SeqID1707480 1 Otoa 26 2.03% 7 intronic 16849 Wt.EFS.Spacer
SeqID6466903 2 Klhl38 83 15.86% 15 intronic 3791 Wt.EFS.Spacer
SeqID2504271 2 Ankfn1 41 5.37% 11 intronic 99709 Wt.EFS.Spacer
SeqID4110068 2 Grem2 27 3.54% 1 -2698 90733 Wt.EFS.Spacer
SeqID4467672 2 Usp24 27 3.54% 4 284393 -284424 2 Wt.EFS.Spacer
SeqID11533 2 Olfr1211 18 2.36% 2 -1488 2424 Wt.EFS.Spacer
SeqID3928647 2 Tsr2 18 2.36% X intronic 6731 Wt.EFS.Spacer
SeqID3928647 2 Fgd1 18 2.36% X 228 43600 Wt.EFS.Spacer
SeqID4836488 2 Slc41a2 18 2.36% 10 intronic 38093 Wt.EFS.Spacer
SeqID1675022 2 Sod3 14 1.83% 5 intronic 5296 Wt.EFS.Spacer
SeqID4384147 3 Gm1574 10343 74.60% 13 19063 -19156 Wt.EFS.Spacer
SeqID2337964 3 Smpdl3a 625 4.51% 10 intronic 17039 Wt.EFS.Spacer
SeqID6527559 3 Vstm2l 375 3.90% 2 intronic 10662 Wt.EFS.Spacer
SeqID2619595 3 Hs3st1 299 2.77% 5 -74773 216314 Wt.EFS.Spacer
SeqID3572513 3 Oxr1 196 1.41% 15 93769 -93848 Wt.EFS.Spacer
SeqID3642672 3 4930402K13Rik 187 1.36% X 12279 14060 Wt.EFS.Spacer
SeqID4598140 3 1700010I14Rik 162 1.23% 17 217316 -217341 1 Wt.EFS.Spacer
SeqID53789 3 Gm8994 145 1.05% 6 52683 -52763 Wt.EFS.Spacer
SeqID4597121 3 Fchsd2 48 0.35% 7 intronic 48599 4 Wt.EFS.Spacer
SeqID2721847 3 Nell1 44 0.32% 7 144467 1034859 Wt.EFS.Spacer
SeqID6629317 3 Tex2 43 0.31% 11 -68347 -68384 1 Wt.EFS.Spacer
SeqID569910 4 Thumpd3 1564 33.40% 6 37331 -37411 2 Wt.EFS.Spacer
SeqID3138597 4 Tsr2 604 12.98% X intronic 6731 Wt.EFS.Spacer
SeqID3138597 4 Fgd1 604 12.98% X 232 43604 Wt.EFS.Spacer
SeqID3112660 4 Kcna10 411 9.01% 3 2172 -2270 Wt.EFS.Spacer
SeqID6459712 4 Nap1l5 190 6.92% 6 -19260 21153 Wt.EFS.Spacer
SeqID5298349 4 Lcorl 179 4.70% 5 -47105 -47136 1 Wt.EFS.Spacer
SeqID58947 4 Prss36 80 1.79% 7 -7287 -7384 Wt.EFS.Spacer
SeqID58947 4 Fus 80 1.79% 7 13347 -13444 Wt.EFS.Spacer
SeqID58947 4 Myst1 80 1.79% 7 28180 41496 Wt.EFS.Spacer
SeqID4917017 4 4632404H12Rik 62 1.37% 3 intronic 4429 Wt.EFS.Spacer
SeqID1852058 4 Otoa 56 1.24% 7 intronic 16870 Wt.EFS.Spacer
SeqID3249122 4 Fgfbp1 46 0.98% 5 -15631 18529 Wt.EFS.Spacer
SeqID6400041 4 Aldh2 43 1.07% 5 intronic 19266 Wt.EFS.Spacer
SeqID3612652 4 Fam5c 28 1.20% 1 143219 -143242 Wt.EFS.Spacer
SeqID3329693 11 Mir122a 2469 35.66% 18 33455 -33551 Wt.LCR.EFS.RPS19
SeqID1720765 11 Spock1 1095 15.28% 13 intronic 285168 Wt.LCR.EFS.RPS19
SeqID6418278 11 Syt13 466 6.48% 2 13367 54328 Wt.LCR.EFS.RPS19
SeqID2944184 11 Gse1 456 6.38% 8 38190 -38243 6 Wt.LCR.EFS.RPS19
SeqID3029594 11 Smo 221 3.06% 6 intronic 9439 Wt.LCR.EFS.RPS19
SeqID5015274 11 9330154K18Rik 98 2.45% 15 -59002 -59078 Wt.LCR.EFS.RPS19
SeqID1182811 11 Map4k2 58 0.83% 19 intronic 10045 Wt.LCR.EFS.RPS19
SeqID1182811 11 Sf1 58 0.83% 19 12450 -12510 Wt.LCR.EFS.RPS19
SeqID1182811 11 Men1 58 0.83% 19 10288 16201 Wt.LCR.EFS.RPS19
SeqID1182811 11 Rasgrp2 58 0.83% 19 48100 -48160 4 Wt.LCR.EFS.RPS19
SeqID3113489 11 Ckap2l 52 0.72% 2 intronic 287 Wt.LCR.EFS.RPS19
SeqID3113489 11 Il1a 52 0.72% 2 -2684 13047 Wt.LCR.EFS.RPS19
SeqID1164543 11 Sort1 47 0.65% 3 intronic 44728 Wt.LCR.EFS.RPS19
SeqID5147166 11 Ttc23l 47 0.69% 15 -1151 -1230 Wt.LCR.EFS.RPS19
SeqID3641389 11 Kcns1 39 0.71% 2 -28837 36332 1 Wt.LCR.EFS.RPS19
SeqID5265118 11 Ttc1 29 0.51% 11 intronic 16637 Wt.LCR.EFS.RPS19
SeqID5153003 11 Mgll 26 0.53% 6 intronic 37742 1 Wt.LCR.EFS.RPS19
SeqID5403262 12 Spag16 4401 66.87% 1 intronic 229362 Wt.LCR.EFS.RPS19
SeqID5801105 12 Tssc1 417 6.15% 12 272564 388228 Wt.LCR.EFS.RPS19
SeqID5439955 12 Tex2 181 3.03% 11 -68381 -68410 1 Wt.LCR.EFS.RPS19
SeqID145626 12 Fggy 163 2.38% 4 intronic 86125 Wt.LCR.EFS.RPS19
SeqID3632824 12 A330032B11Rik 137 2.67% 19 103340 -103416 Wt.LCR.EFS.RPS19
SeqID3513274 12 Id4 82 1.42% 13 76167 -76193 Wt.LCR.EFS.RPS19
SeqID2573674 21 Gm8910 3981 55.67% 3 -15914 -15954 Wt.LCR.EFS.RPS19
SeqID4578111 21 Sfi1 1334 17.42% 11 -2411 64025 Wt.LCR.EFS.RPS19
SeqID6032595 21 1810012P15Rik 510 6.22% 11 20115 40402 Wt.LCR.EFS.RPS19
SeqID2190941 21 Sec13 304 3.71% 6 -138251 -138303 Wt.LCR.EFS.RPS19
SeqID4887823 21 Cand1 116 1.42% 10 intronic 38024 Wt.LCR.EFS.RPS19
SeqID3908770 21 Gm8910 86 1.99% 3 -15860 -15888 Wt.LCR.EFS.RPS19
SeqID5816349 21 Gtf3c1 74 0.98% 7 intronic 1501 Wt.LCR.EFS.RPS19
SeqID5961090 22 B3gnt2 2194 48.55% 11 -26770 52985 2 Wt.LCR.EFS.RPS19
SeqID1379082 22 Arhgap21 854 21.09% 2 -19558 140521 1 Wt.LCR.EFS.RPS19
SeqID1695057 22 Nr2f1 320 8.21% 13 -458602 -458640 Wt.LCR.EFS.RPS19
SeqID4302263 22 Fchsd2 100 2.24% 7 intronic 33260 4 Wt.LCR.EFS.RPS19
SeqID4146056 22 Pth1r 65 1.44% 9 intronic 20669 Wt.LCR.EFS.RPS19
SeqID1010799 22 Fos 47 1.06% 12 36438 39822 6 Wt.LCR.EFS.RPS19
SeqID1204764 22 Slitrk3 46 1.08% 3 -24849 -24973 Wt.LCR.EFS.RPS19
SeqID4473143 The light blue color indicates that the same SeqID is present more than once in the table. We reported the closest gene, if there was not an intronic hit or any gene within
50 kb TSS distance listed in one of the databases.
6 Found in database with x tumours associated to the gene listed in the retroviral tagged cancer gene database (RTCGD).
Not found in any of the databases.
Legend: 
BC = Barcode of index primer; Chr. = Chromosome; TSS = Transcriptional Start Site; CIS = common integration site; RTCGD = Retroviral Tagged Cancer Gene Database (Akagi et al., Nucleic Acids 
Res. 2004); NCG = Network of Cancer Genes - Version 5 (http://ncg.kcl.ac.uk/); Bushman = Bushman Cancer Gene List (http://www.bushmanlab.org/links/genelists); Deichmann = referring to 
Deichmann et al., Mol Ther. 2011, as a list of insertions found in clinical and preclinical insertion site screens (this is not a cancer database per se). 
Gene
Symbol
Chr.
Raw
Distance
TSS
Distance
CIS RTCGD NCG Bushman Deichmann
Mid1 X intronic 318851 21 8
Lrp1b 2 intronic 1656003 11
Gm10664 8 -245218 -245275 8
Clasp2 9 intronic 30094 8
Rab2a 4 56175 -56215 7
Gm22 8 104488 -104604 7
Gm44 X 5129 6122 7
Ckap2l 2 intronic 33 6
Gm6531 8 24919 -24953 6
Fkbp6 5 intronic 58173 6
1700054O13Rik X 51371 -51409 6
Otoa 7 intronic 16953 6
Nub1 5 intronic 16737 6 1
Lamb1 12 intronic 43839 6
St5 7 intronic 15469 5 1
Samd9l 6 -228431 255746 5
Ch25h 19 -85477 86827 5 2
C230021G24Rik 10 -170787 -170830 5
Gm9966 7 487811 -487858 5
Ldlrad2 4 -9076 12844 5
Xrcc6bp1 10 -290161 323103 5 1
Acss3 10 intronic 85789 5
Sfi1 11 -1456 63070 5
Prim2 1 intronic 54524 5
Pgap3 11 intronic 3018 5
Pggt1b 18 intronic 33180 5 1
Lingo1 9 intronic 62255 5
Klhl38 15 intronic 3710 5
Tmprss9 10 intronic 5592 5
8 Found in database with x tumours associated to the IS.
Not found in database
Legend: 
Chr. = Chromosome; TSS = Transcriptional Start Site; CIS = common integration site; RTCGD = Retroviral Tagged Cancer Gene 
Database (Akagi et al., Nucleic Acids Res. 2004); NCG = Network of Cancer Genes (http://ncg.kcl.ac.uk/); Bushman = Bushman 
Cancer Gene List (http://www.bushmanlab.org/links/genelists); Deichmann = referring to Deichmann et al., Mol Ther. 2011. 
